FDA-approved
Heart & blood
Bivalirudin
Evidence
FDA approved
Class
Direct thrombin inhibitor
KEY TAKEAWAY
Bivalirudin is a synthetic peptide anticoagulant used during angioplasty and stent procedures. It blocks thrombin directly to prevent clots.
Written by the Veylo editorial team · Updated
November 2026
What it is
A synthetic copy of a leech-derived anticoagulant
Approved for
Anticoagulation during percutaneous coronary intervention
Key fact
Lowered bleeding compared with heparin plus a platelet inhibitor in heart attack patients
Route
Intravenous infusion
Evidence strength
FDA approved
Bivalirudin, sold as Angiomax, is a 20-amino-acid peptide based on hirudin, a clotting inhibitor from medicinal leeches.
It binds directly to thrombin, the enzyme that forms clots, and blocks its activity for a short time.
The FDA approved bivalirudin in 2000 for use during percutaneous coronary intervention.
Anticoagulation during angioplasty and stenting, including in people who cannot take heparin.
Bleeding is the main risk. Low blood pressure and allergic reactions are less common.
Stone GW et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.